The Effect of Apalutamide on Thyroid Function in Prostate Cancer Patients.

Clare MoffattMelissa G LechnerTrevor E AngellJohn ShenAlexandra DrakakiGonzalo J AcostaTom Z LiangKaren Tsai

Published in: Journal of the Endocrine Society (2024)

APT-associated thyroid dysfunction presents as new or worsening hypothyroidism and should prompt initiation or increase in thyroid hormone replacement. Monitoring of thyroid function tests is recommended every 1 to 2 months for all patients on APT and 2 to 3 months after completion of APT.

Keyphrases

end stage renal disease
prostate cancer
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
prognostic factors
peritoneal dialysis
patient reported outcomes
benign prostatic hyperplasia